首页> 外文期刊>Infectious Diseases and Therapy >Tenofovir: What We Have Learnt After 7.5?Million Person-Years of Use
【24h】

Tenofovir: What We Have Learnt After 7.5?Million Person-Years of Use

机译:替诺福韦:7.5年后我们学到了什么?百万人年使用

获取原文
           

摘要

Tenofovir was licensed for use in patients with HIV in 2001 and since then has become a firmly established anti-retroviral in both guidelines and routine practice. Data have been presented from many pivotal studies—informing on its efficacy, use, and adverse features—and there are also over 7.5?million patient-years of experience to date. We explore the data on this nucleotide reverse transcriptase inhibitor in HIV presented since 2008—focusing on efficacy, side effects, and utility.
机译:替诺福韦(Tenofovir)于2001年获得艾滋病毒患者的使用许可,此后在指导方针和常规实践中已成为牢固确立的抗逆转录病毒药物。已经从许多关键性研究中提供了数据,包括其功效,用途和不良特征,并且迄今为止,已有超过750万患者-年的经验。我们探索了自2008年以来出现的艾滋病毒中这种核苷酸逆转录酶抑制剂的数据,重点是功效,副作用和效用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号